Table 3.
Patients reporting ≥1 antibiotic by class, and mean duration of antibiotic use, for patients administered antibiotics under Prescribing Scenario C and Scenario B/C- by patient status and country
| Outpatient | Inpatient | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Argentina | Hungary | Mexico | Peru | Poland | Total | Argentina | Hungary | Mexico | Peru | Poland | Total | |
| Patients prescribed antibiotics according to Scenario C, N | – | 1 | – | – | – | 1 | 2 | 2 | 2 | 1 | 9 | 16 |
| Mean (95% CI) duration of use of antibiotics, Scenario C, days | – | 7.0 (3.3, 14.7) | – | – | – | 7.0 (3.3, 14.7) | 6.0 (3.4,10.6) | 5.5 (3.0, 9.9) | 5.5 (3.0, 9.9) | 5.0 (2.1, 12.0) | 5.4 (4.1, 7.2) | 5.5 (4.2, 7.2) |
| Patients prescribed ≥1 antibiotic, by class, Scenario C, n (%) a,c | ||||||||||||
| β-lactam agent | – | 1 (100.0) | – | – | – | 1 (100.0) | 1 (50.0) | 2 (100.0) | 2 (100.0) | 1 (100.0) | 8 (88.9) | 14 (87.5) |
| Aminoglycide | – | – | – | – | – | – | 1 (50.0) | – | 1 (50.0) | – | – | 2 (12.5) |
| Lincosamide | – | – | – | – | – | – | 1 (50.0) | 1 (50.0) | 1 (50.0) | – | – | 3 (18.8) |
| Macrolide | – | – | – | – | – | – | – | – | – | – | 1 (11.1) | 1 (6.3) |
| Patients prescribed antibiotics according to Scenario B/C, N | 16 | 2 | 6 | 17 | 8 | 49 | 50 | 40 | 49 | 54 | 38 | 231 |
| Mean (95% CI) duration of use of antibiotics, Scenario B/C, days | 9.5 (8.0, 11.2) | 7.0 (4.1, 11.8) | 8.2 (6.2, 10.8) | 6.5 (5.4, 7.8) | 8.5 (6.7,10.8) | 7.9 (6.8, 9.0) | 8.9 (8.1, 9.8) | 7.2 (6.4,8.1) | 15.8 (14.8, 17.0) | 14.9 (13.9, 16.0) | 8.1 (7.3, 9.1) | 10.4 (10.0, 10.9) |
| Patients prescribed ≥1 antibiotic, by class, under Scenario B/C n (%)b,c | ||||||||||||
| β-lactam agent | 15 (93.8) | 2 (100.0) | 4 (66.7) | 12 (70.6) | 7 (87.5) | 40 (81.6) | 28 (56.0) | 38 (95.0) | 44 (89.8) | 54 (100.0) | 34 (84.5) | 198 (85.7) |
| Lincosamide | 6 (37.5) | – | 3 (50.0) | – | – | 9 (18.4) | 35 (70.0) | 6 (15.0) | 29 (59.2) | 24 (44.4) | 3 (7.9) | 97(42.0) |
| Aminoglycide | – | – | – | 1 (5.9) | – | 1 (100.0) | 5 (10.0) | 6 (15.0) | 5 (10.2) | 1 (1.9) | 1 (2.6) | 18 (7.8) |
| Glycopeptide | – | – | – | – | – | – | 2 (4.0) | – | 8 (16.3) | 4 (7.4) | 1 (2.6) | 15 (6.5) |
| Other | 6 (37.5) | – | 1 (16.7) | 5 (29.4) | 1 (12.5) | 13 (26.5) | 11 (22.0) | – | 3 (6.1) | 1 (1.9) | 1 (2.6) | 15 (6.5) |
| Macrolide | – | – | – | 1 (5.9) | 1 (12.5) | 2 (4.1) | – | – | 1 (2.0) | – | 3 (7.9) | 4 (17.3) |
| Fluoroquinolone | – | – | – | – | – | – | – | 1 (2.5) | 2 (4.0) | – | 1 (2.6) | 4 (1.7) |
CI Confidence Interval
a Among population of patients under prescribing scenario C
b Among population of patients under prescribing scenario B + C
c Reported for classes of antibiotics administered to > 1.0% of the total inpatient and/or outpatient population